drugset
Drugs / AZD5148
last change Dec 2025 re-read 3 minutes ago

AZD5148

Monoclonal antibody

Developed for
Clostridium difficile colitis
Investigated by
AstraZeneca

Trials 3

today NCT07285213 · Ph 2 NCT06639997 · Ph 1 NCT06469151 · Ph 1
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06639997 Oct 2024 → Dec 2025 Clostridium difficile colitis AstraZeneca Completed No outcome recorded
Phase 1 NCT06469151 Jun 2024 → Oct 2025 — AstraZeneca Completed No outcome recorded
Phase 21 trial
Phase 2 NCT07285213 Dec 2025 → Apr 2027 expected Clostridium difficile colitis AstraZeneca Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2024-10-16 AstraZeneca Results AstraZeneca advances science of infectious disease protection at IDWeek 2024 astrazeneca.com ↗
Pre-clinical data will be shared showing that AZD5148, an anti-toxin B neutralizing monoclonal antibody now in Phase I trials, may provide protection against Clostridioides difficile (C. diff) infection, a condition that can cause life-threatening diarrhea and intestinal inflammation.
2024-04-17 AstraZeneca Results AstraZeneca advances the science of infectious disease protection at ECCMID 2024 astrazeneca.com ↗
Anti-toxin B neutralizing mAb AZD5148 provides protection in a Clostridioides difficile gnotobiotic piglet model

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as AZD5148 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06469151 ↗
2

NCT07285213 ↗

NCT06639997 ↗
Modality Monoclonal antibody “AZD5148 Monoclonal Antibody” NCT07285213 ↗
Route Intramuscular “as an IM injection” NCT06469151 ↗